Overview

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Status:
Active, not recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This study is a multicentric, single arm phase II trial to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by Cisplatinum-Cytarabine-Dexamethasone (DHAP) followed by autologous transplantation plus obinutuzumab maintenance then Molecular Residual Disease (MRD) driven maintenance

Phase:

Phase 2

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Treatments:

Carmustine
Cisplatin
Cytarabine
Dexamethasone
Etoposide
Melphalan
Obinutuzumab